Vedolizumab vs placebo
Induction of clinical response (6–10 weeks) · people with Crohn's disease
Vedolizumab leads to higher induction of clinical response (6–10 weeks) compared with placebo (high certainty).
1 finding from 1 review
- Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.43 [1.19, 1.71]4 studies · 1126 participantsHigh